The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to Case Western Reserve University in the amount of $502,516 to investigate the effects of newly developed small molecule nuclear heat shock transcription factor 1 (HSF1) degraders on acute myeloid leukemia (AML) stem cells. The research aims to determine the impact of these HSF1 degraders on AML stem cell self-renewal, elucidate their mechanism of action, and identify associated biomarkers that could help identify AML patients most susceptible to this therapeutic approach. This 5-year research project, starting on April 1, 2025, seeks to advance the clinical translation of these HSF1 degraders as a potential treatment for AML by targeting the underlying leukemic stem cells that drive disease recurrence.
Generated 3/18/25, 1:44 AM